<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530946</url>
  </required_header>
  <id_info>
    <org_study_id>A3841058</org_study_id>
    <nct_id>NCT00530946</nct_id>
  </id_info>
  <brief_title>A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin</brief_title>
  <official_title>A Multi-Center, Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin In The Treatment Of Concurrent Hypertension And Hyper-LDL-Cholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the changes in the trough Systolic Blood Pressure (SBP) and the percent changes in
      Low Density Lipoprotein-Cholesterol (LDL-C) from baseline at Week 8 in the treatment period
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Low Density Lipoprotein-Cholesterol</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure From Baseline to Each Observation Point</measure>
    <time_frame>2 weeks, 4 weeks, and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure From Baseline to Each Observation Point</measure>
    <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Low Density Lipoprotein-Cholesterol From Baseline to Each Observation Point</measure>
    <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol From Baseline to Each Observation Point</measure>
    <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High Density Lipoprotein-Cholesterol From Baseline to Each Observation Point</measure>
    <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides From Baseline to Each Observation Point</measure>
    <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low Density Lipoprotein-Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (LDL-C/HDL-C) From Baseline to Each Observation Point</measure>
    <time_frame>2 weeks, 4 weeks, and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (TC/HDL-C) From Baseline to Each Observation Point</measure>
    <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apolipoprotein B From Baseline to Each Observation Point</measure>
    <time_frame>2 weeks, 4 weeks, and 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Hypertension</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>CI-1038 2.5mg/5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CI-1038 2.5mg/10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CI-1038 5mg/5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CI-1038 5mg/10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 2.5mg/Atorvastatin 5mg</intervention_name>
    <description>Single pill combination, dosed once daily for 8 weeks</description>
    <arm_group_label>CI-1038 2.5mg/5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 2.5mg/Atorvastatin 10mg</intervention_name>
    <description>Single pill combination, dosed once daily for 8 weeks</description>
    <arm_group_label>CI-1038 2.5mg/10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg/Atorvastatin 5mg</intervention_name>
    <description>Single pill combination, dosed once daily for 8 weeks</description>
    <arm_group_label>CI-1038 5mg/5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg/Atorvastatin 10mg</intervention_name>
    <description>Single pill combination, dosed once daily for 8 weeks</description>
    <arm_group_label>CI-1038 5mg/10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The out-patient with concurrent hypertension and hyper-LDL-cholesterolemia is a male
             or female &gt;=20 to &lt;80 years of age at Visit 1.

          -  The SBP at Visit 4 (Week -1) and Visit 5 (Week 0) is continuously SBP &gt;=140 mmHg and
             &lt;180 mmHg,

          -  LDL-C &gt;=140 mg/dL and &lt;250 mg/dL at Visit 3 (Week -2) and 4 (Week -1).

        Exclusion Criteria:

          -  Subjects who had experienced the following coronary artery disease within the past 3
             months.

          -  Myocardial infarction

          -  Receiving PCI（percutaneous coronary intervention）or CABG (coronary artery bypass
             grafting)

          -  Any clinically meaningful valvular disease

          -  Subjects with a history of cerebrovascular diseases such as stroke or transient
             ischemic attack within the past 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maebaru-shi</city>
        <state>Fukuoka-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Annaka</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Teine</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yamashita-cho</city>
        <state>Naka-ku, Kanagawa-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kita-ku</city>
        <state>Osaka-fu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koshigaya-shi</city>
        <state>Saitama-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chofu</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kiyose</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinagawa-Ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinagawa</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3841058&amp;StudyName=A%20Randomized%20Study%20To%20Evaluate%20Efficacy%20And%20Safety%20Of%20A%20Fixed%20Combination%20Therapy%20Of%20Amlodipine%20And%20Atorvastatin</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <results_first_submitted>March 10, 2009</results_first_submitted>
  <results_first_submitted_qc>March 10, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2009</results_first_posted>
  <last_update_submitted>April 28, 2009</last_update_submitted>
  <last_update_submitted_qc>April 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Amlodipine, atorvastatin drug combination</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty (20) centers in Japan</recruitment_details>
      <pre_assignment_details>A total of 301 subjects entered the 6-week diet observation period and the end of diet observation period, 165 subjects who met all the inclusion criteria for the treatment period and had no conflict to exclusion criteria were randomized to 4 CI-1038 groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CI-1038 2.5 mg/5 mg</title>
          <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
        </group>
        <group group_id="P2">
          <title>CI-1038 2.5 mg/10 mg</title>
          <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
        </group>
        <group group_id="P3">
          <title>CI-1038 5 mg/5 mg</title>
          <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
        </group>
        <group group_id="P4">
          <title>CI-1038 5 mg/10 mg</title>
          <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CI-1038 2.5 mg/5 mg</title>
          <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
        </group>
        <group group_id="B2">
          <title>CI-1038 2.5 mg/10 mg</title>
          <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
        </group>
        <group group_id="B3">
          <title>CI-1038 5 mg/5 mg</title>
          <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
        </group>
        <group group_id="B4">
          <title>CI-1038 5 mg/10 mg</title>
          <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 to 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic Blood Pressure</title>
        <description>Value at Week 8 minus value at baseline</description>
        <time_frame>8 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>CI-1038 2.5 mg/5 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
          </group>
          <group group_id="O2">
            <title>CI-1038 2.5 mg/10 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
          </group>
          <group group_id="O3">
            <title>CI-1038 5 mg/5 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
          </group>
          <group group_id="O4">
            <title>CI-1038 5 mg/10 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure</title>
          <description>Value at Week 8 minus value at baseline</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.6" spread="1.65"/>
                    <measurement group_id="O2" value="-15.9" spread="1.69"/>
                    <measurement group_id="O3" value="-21.8" spread="1.69"/>
                    <measurement group_id="O4" value="-18.9" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Low Density Lipoprotein-Cholesterol</title>
        <description>Percent of &quot;value at Week 8 minus value at baseline&quot; over value at baseline</description>
        <time_frame>8 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>CI-1038 2.5 mg/5 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
          </group>
          <group group_id="O2">
            <title>CI-1038 2.5 mg/10 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
          </group>
          <group group_id="O3">
            <title>CI-1038 5 mg/5 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
          </group>
          <group group_id="O4">
            <title>CI-1038 5 mg/10 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low Density Lipoprotein-Cholesterol</title>
          <description>Percent of &quot;value at Week 8 minus value at baseline&quot; over value at baseline</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.2" spread="1.49"/>
                    <measurement group_id="O2" value="-42.5" spread="1.52"/>
                    <measurement group_id="O3" value="-34.3" spread="1.52"/>
                    <measurement group_id="O4" value="-40.6" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure From Baseline to Each Observation Point</title>
        <description>Value at Week 2, Week 4, or Week 8 minus value at baseline</description>
        <time_frame>2 weeks, 4 weeks, and 8 weeks</time_frame>
        <population>Full Analysis Set, Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>CI-1038 2.5 mg/5 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
          </group>
          <group group_id="O2">
            <title>CI-1038 2.5 mg/10 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
          </group>
          <group group_id="O3">
            <title>CI-1038 5 mg/5 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
          </group>
          <group group_id="O4">
            <title>CI-1038 5 mg/10 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure From Baseline to Each Observation Point</title>
          <description>Value at Week 2, Week 4, or Week 8 minus value at baseline</description>
          <population>Full Analysis Set, Observed Cases</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="9.63"/>
                    <measurement group_id="O2" value="-13.5" spread="10.18"/>
                    <measurement group_id="O3" value="-19.2" spread="10.53"/>
                    <measurement group_id="O4" value="-16.0" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.2" spread="10.26"/>
                    <measurement group_id="O2" value="-14.6" spread="12.33"/>
                    <measurement group_id="O3" value="-20.2" spread="11.08"/>
                    <measurement group_id="O4" value="-19.6" spread="11.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.8" spread="11.40"/>
                    <measurement group_id="O2" value="-15.3" spread="11.59"/>
                    <measurement group_id="O3" value="-21.3" spread="10.07"/>
                    <measurement group_id="O4" value="-18.7" spread="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure From Baseline to Each Observation Point</title>
        <description>Value at Week 2, Week 4, or Week 8 minus value at baseline</description>
        <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
        <population>Full Analysis Set, Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>CI-1038 2.5 mg/5 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
          </group>
          <group group_id="O2">
            <title>CI-1038 2.5 mg/10 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
          </group>
          <group group_id="O3">
            <title>CI-1038 5 mg/5 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
          </group>
          <group group_id="O4">
            <title>CI-1038 5 mg/10 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure From Baseline to Each Observation Point</title>
          <description>Value at Week 2, Week 4, or Week 8 minus value at baseline</description>
          <population>Full Analysis Set, Observed Cases</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="6.23"/>
                    <measurement group_id="O2" value="-6.0" spread="6.05"/>
                    <measurement group_id="O3" value="-8.1" spread="6.24"/>
                    <measurement group_id="O4" value="-8.2" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="4.96"/>
                    <measurement group_id="O2" value="-8.2" spread="7.13"/>
                    <measurement group_id="O3" value="-9.4" spread="6.19"/>
                    <measurement group_id="O4" value="-9.2" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="6.34"/>
                    <measurement group_id="O2" value="-8.7" spread="8.06"/>
                    <measurement group_id="O3" value="-12.0" spread="6.31"/>
                    <measurement group_id="O4" value="-9.9" spread="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Low Density Lipoprotein-Cholesterol From Baseline to Each Observation Point</title>
        <description>Percent of &quot;value at Week 2, Week 4, or Week 8 minus value at baseline&quot; over value at baseline</description>
        <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
        <population>Full Analysis Set, Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>CI-1038 2.5 mg/5 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
          </group>
          <group group_id="O2">
            <title>CI-1038 2.5 mg/10 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
          </group>
          <group group_id="O3">
            <title>CI-1038 5 mg/5 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
          </group>
          <group group_id="O4">
            <title>CI-1038 5 mg/10 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low Density Lipoprotein-Cholesterol From Baseline to Each Observation Point</title>
          <description>Percent of &quot;value at Week 2, Week 4, or Week 8 minus value at baseline&quot; over value at baseline</description>
          <population>Full Analysis Set, Observed Cases</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.8" spread="9.11"/>
                    <measurement group_id="O2" value="-42.5" spread="11.00"/>
                    <measurement group_id="O3" value="-32.8" spread="9.15"/>
                    <measurement group_id="O4" value="-40.2" spread="13.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.4" spread="7.67"/>
                    <measurement group_id="O2" value="-43.8" spread="9.30"/>
                    <measurement group_id="O3" value="-35.0" spread="9.19"/>
                    <measurement group_id="O4" value="-41.8" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.6" spread="7.80"/>
                    <measurement group_id="O2" value="-42.9" spread="10.28"/>
                    <measurement group_id="O3" value="-34.2" spread="9.22"/>
                    <measurement group_id="O4" value="-40.8" spread="11.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol From Baseline to Each Observation Point</title>
        <description>Percent of &quot;value at Week 2, Week 4, or Week 8 minus value at baseline&quot; over value at baseline</description>
        <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
        <population>Full Analysis Set, Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>CI-1038 2.5 mg/5 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
          </group>
          <group group_id="O2">
            <title>CI-1038 2.5 mg/10 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
          </group>
          <group group_id="O3">
            <title>CI-1038 5 mg/5 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
          </group>
          <group group_id="O4">
            <title>CI-1038 5 mg/10 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol From Baseline to Each Observation Point</title>
          <description>Percent of &quot;value at Week 2, Week 4, or Week 8 minus value at baseline&quot; over value at baseline</description>
          <population>Full Analysis Set, Observed Cases</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.2" spread="6.86"/>
                    <measurement group_id="O2" value="-30.5" spread="8.44"/>
                    <measurement group_id="O3" value="-23.0" spread="7.22"/>
                    <measurement group_id="O4" value="-28.3" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.6" spread="6.36"/>
                    <measurement group_id="O2" value="-31.5" spread="7.08"/>
                    <measurement group_id="O3" value="-24.7" spread="7.64"/>
                    <measurement group_id="O4" value="-28.6" spread="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.1" spread="6.01"/>
                    <measurement group_id="O2" value="-30.0" spread="8.43"/>
                    <measurement group_id="O3" value="-23.4" spread="7.78"/>
                    <measurement group_id="O4" value="-28.2" spread="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High Density Lipoprotein-Cholesterol From Baseline to Each Observation Point</title>
        <description>Percent of &quot;value at Week 2, Week 4, or Week 8 minus value at baseline&quot; over value at baseline</description>
        <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
        <population>Full Analysis Set, Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>CI-1038 2.5 mg/5 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
          </group>
          <group group_id="O2">
            <title>CI-1038 2.5 mg/10 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
          </group>
          <group group_id="O3">
            <title>CI-1038 5 mg/5 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
          </group>
          <group group_id="O4">
            <title>CI-1038 5 mg/10 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High Density Lipoprotein-Cholesterol From Baseline to Each Observation Point</title>
          <description>Percent of &quot;value at Week 2, Week 4, or Week 8 minus value at baseline&quot; over value at baseline</description>
          <population>Full Analysis Set, Observed Cases</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="12.11"/>
                    <measurement group_id="O2" value="8.3" spread="10.70"/>
                    <measurement group_id="O3" value="6.6" spread="9.12"/>
                    <measurement group_id="O4" value="9.9" spread="10.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="8.16"/>
                    <measurement group_id="O2" value="7.9" spread="13.03"/>
                    <measurement group_id="O3" value="9.3" spread="13.24"/>
                    <measurement group_id="O4" value="11.9" spread="13.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="10.86"/>
                    <measurement group_id="O2" value="7.5" spread="13.27"/>
                    <measurement group_id="O3" value="9.7" spread="10.59"/>
                    <measurement group_id="O4" value="10.8" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides From Baseline to Each Observation Point</title>
        <description>Percent of &quot;value at Week 2, Week 4, or Week 8 minus value at baseline&quot; over value at baseline</description>
        <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
        <population>Full Analysis Set, Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>CI-1038 2.5 mg/5 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
          </group>
          <group group_id="O2">
            <title>CI-1038 2.5 mg/10 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
          </group>
          <group group_id="O3">
            <title>CI-1038 5 mg/5 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
          </group>
          <group group_id="O4">
            <title>CI-1038 5 mg/10 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides From Baseline to Each Observation Point</title>
          <description>Percent of &quot;value at Week 2, Week 4, or Week 8 minus value at baseline&quot; over value at baseline</description>
          <population>Full Analysis Set, Observed Cases</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.1" spread="33.82"/>
                    <measurement group_id="O2" value="-27.4" spread="22.48"/>
                    <measurement group_id="O3" value="-16.2" spread="20.00"/>
                    <measurement group_id="O4" value="-23.9" spread="24.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.2" spread="25.31"/>
                    <measurement group_id="O2" value="-25.7" spread="18.15"/>
                    <measurement group_id="O3" value="-15.1" spread="22.42"/>
                    <measurement group_id="O4" value="-23.2" spread="28.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.1" spread="19.72"/>
                    <measurement group_id="O2" value="-21.1" spread="21.68"/>
                    <measurement group_id="O3" value="-10.8" spread="31.42"/>
                    <measurement group_id="O4" value="-24.0" spread="25.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Low Density Lipoprotein-Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (LDL-C/HDL-C) From Baseline to Each Observation Point</title>
        <description>Value at Week 2, Week 4, or Week 8 minus value at baseline</description>
        <time_frame>2 weeks, 4 weeks, and 8 weeks</time_frame>
        <population>Full Analysis Set, Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>CI-1038 2.5 mg/5 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
          </group>
          <group group_id="O2">
            <title>CI-1038 2.5 mg/10 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
          </group>
          <group group_id="O3">
            <title>CI-1038 5 mg/5 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
          </group>
          <group group_id="O4">
            <title>CI-1038 5 mg/10 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low Density Lipoprotein-Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (LDL-C/HDL-C) From Baseline to Each Observation Point</title>
          <description>Value at Week 2, Week 4, or Week 8 minus value at baseline</description>
          <population>Full Analysis Set, Observed Cases</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.58"/>
                    <measurement group_id="O2" value="-1.4" spread="0.42"/>
                    <measurement group_id="O3" value="-1.1" spread="0.49"/>
                    <measurement group_id="O4" value="-1.3" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.41"/>
                    <measurement group_id="O2" value="-1.4" spread="0.42"/>
                    <measurement group_id="O3" value="-1.2" spread="0.56"/>
                    <measurement group_id="O4" value="-1.4" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.37"/>
                    <measurement group_id="O2" value="-1.4" spread="0.44"/>
                    <measurement group_id="O3" value="-1.2" spread="0.52"/>
                    <measurement group_id="O4" value="-1.4" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (TC/HDL-C) From Baseline to Each Observation Point</title>
        <description>Value at Week 2, Week 4, or Week 8 minus value at baseline</description>
        <time_frame>2 weeks, 4 weeks , and 8 weeks</time_frame>
        <population>Full Analysis Set, Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>CI-1038 2.5 mg/5 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
          </group>
          <group group_id="O2">
            <title>CI-1038 2.5 mg/10 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
          </group>
          <group group_id="O3">
            <title>CI-1038 5 mg/5 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
          </group>
          <group group_id="O4">
            <title>CI-1038 5 mg/10 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (TC/HDL-C) From Baseline to Each Observation Point</title>
          <description>Value at Week 2, Week 4, or Week 8 minus value at baseline</description>
          <population>Full Analysis Set, Observed Cases</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.71"/>
                    <measurement group_id="O2" value="-1.6" spread="0.49"/>
                    <measurement group_id="O3" value="-1.2" spread="0.61"/>
                    <measurement group_id="O4" value="-1.5" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.48"/>
                    <measurement group_id="O2" value="-1.6" spread="0.49"/>
                    <measurement group_id="O3" value="-1.4" spread="0.69"/>
                    <measurement group_id="O4" value="-1.6" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.43"/>
                    <measurement group_id="O2" value="-1.5" spread="0.51"/>
                    <measurement group_id="O3" value="-1.4" spread="0.65"/>
                    <measurement group_id="O4" value="-1.5" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Apolipoprotein B From Baseline to Each Observation Point</title>
        <description>Value at Week 2, Week 4, or Week 8 minus value at baseline</description>
        <time_frame>2 weeks, 4 weeks, and 8 weeks</time_frame>
        <population>Full Analysis Set, Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>CI-1038 2.5 mg/5 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
          </group>
          <group group_id="O2">
            <title>CI-1038 2.5 mg/10 mg</title>
            <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
          </group>
          <group group_id="O3">
            <title>CI-1038 5 mg/5 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
          </group>
          <group group_id="O4">
            <title>CI-1038 5 mg/10 mg</title>
            <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Apolipoprotein B From Baseline to Each Observation Point</title>
          <description>Value at Week 2, Week 4, or Week 8 minus value at baseline</description>
          <population>Full Analysis Set, Observed Cases</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.6" spread="12.55"/>
                    <measurement group_id="O2" value="-45.8" spread="12.11"/>
                    <measurement group_id="O3" value="-33.5" spread="9.86"/>
                    <measurement group_id="O4" value="-44.4" spread="15.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.1" spread="10.94"/>
                    <measurement group_id="O2" value="-47.2" spread="10.20"/>
                    <measurement group_id="O3" value="-36.6" spread="11.36"/>
                    <measurement group_id="O4" value="-45.8" spread="13.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.2" spread="9.65"/>
                    <measurement group_id="O2" value="-46.4" spread="10.87"/>
                    <measurement group_id="O3" value="-36.6" spread="12.27"/>
                    <measurement group_id="O4" value="-45.1" spread="14.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CI-1038 2.5 mg/5 mg</title>
          <description>Amlodipine 2.5 mg/Atorvastatin 5 mg single pill combination (CI-1038 2.5mg/5mg)</description>
        </group>
        <group group_id="E2">
          <title>CI-1038 2.5 mg/10 mg</title>
          <description>Amlodipine 2.5 mg/Atorvastatin 10 mg single pill combination (CI-1038 2.5 mg/10 mg)</description>
        </group>
        <group group_id="E3">
          <title>CI-1038 5 mg/5 mg</title>
          <description>Amlodipine 5 mg/Atorvastatin 5 mg single pill combination (CI-1038 5 mg/5 mg)</description>
        </group>
        <group group_id="E4">
          <title>CI-1038 5 mg/10 mg</title>
          <description>Amlodipine 5 mg/Atorvastatin 10 mg single pill combination (CI-1038 5 mg/10 mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="0"/>
                <counts group_id="E3" subjects_affected="0"/>
                <counts group_id="E4" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6"/>
                <counts group_id="E2" subjects_affected="7"/>
                <counts group_id="E3" subjects_affected="8"/>
                <counts group_id="E4" subjects_affected="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

